FDA NDA · NDA218436
RHAPSIDO
Sponsor: NOVARTIS
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
NDA218436
TYPE
NDA
ORIGINAL APPROVAL
2025-09-30
LATEST ACTION
2026-10-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
RHAPSIDO · ReferencePrescription
REMIBRUTINIB 25MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →